AAM issues statement on the Trump Administration’s “Most Favored Nation” model
WASHINGTON — AAM and its Biosimilars Council commend the Administration for today’s effort to remove perverse rebate incentives now blocking competition in the U.S. prescription drug marketplace, but further action is necessary to modernize the Medicare Part D program and ensure that patients and taxpayers realize the full value of lower cost generic and biosimilar
